Cagrilintide and tirzepatide together: what the evidence actually shows

What the trial data on cagrilintide combinations actually shows

The most clinically advanced cagrilintide combination to reach published trial data is CagriSema — cagrilintide paired with semaglutide, not tirzepatide. Phase 3 results from the REDEFINE programme, as reported by Novo Nordisk, pointed to substantial average weight reductions exceeding 20% over 68 weeks in some cohorts, placing the combination among the most efficacious investigational regimens studied so far. That figure matters here because it sets the comparison point: researchers are exploring whether adding amylin-pathway signalling on top of incretin-based therapy produces additive effects on appetite, gastric emptying and energy intake.

No equivalent published phase 3 data exists for cagrilintide combined with tirzepatide specifically. A handful of early-phase exploratory studies have looked at GIP/GLP-1 dual agonism alongside amylin signalling in rodent and small human cohorts, and the mechanistic case is plausible — the three pathways (GIP, GLP-1 and amylin) converge on appetite regulation through overlapping but distinct brain regions. Whether that mechanistic logic translates to a clinically safe and superior combination in humans is precisely what rigorous trial programmes are designed to establish. The SURMOUNT-1 trial published in the New England Journal of Medicine demonstrates the weight-loss ceiling tirzepatide alone can reach (around 20–21% average body-weight reduction at the 15 mg dose) which itself sets a high bar for any add-on to beat.

A common misconception worth setting aside gently: that combining two powerful weight-loss mechanisms must always produce greater benefit. Biology is not always additive. Overlapping side-effect profiles, receptor saturation and pharmacokinetic interactions each require systematic study before a combination can be considered safe, let alone recommended.

Why no prescriber can currently offer you this combination in the UK

Cagrilintide has no UK marketing authorisation for any indication. Under the Human Medicines Regulations 2012, a medicine must hold a licence before it can be prescribed routinely; cagrilintide is available only within the bounds of approved clinical trials. That is not a technicality, it reflects the evidence standard required to confirm that a medicine's benefits outweigh its risks in a defined population.

Tirzepatide, by contrast, is fully licensed. The NHS patient information for tirzepatide describes the approved indications, dosing schedule and known safety profile. Its licensed use is as a single agent, not in combination with investigational compounds. A prescriber combining a licensed medicine with an unlicensed, non-trial compound would be acting outside the SmPC and outside standard clinical governance, which is why no regulated UK pharmacy, including ours, can offer this. Questions about tirzepatide as a standalone treatment and about Mounjaro's licensed indications are covered in detail elsewhere on the site.

For readers curious about other peptide combinations that sometimes appear alongside tirzepatide in online discussions, the picture is similar: whether the question involves MOTS-c, GHK-Cu, or growth hormone peptides, none of these combinations carries a UK licence. The absence of approval reflects an absence of sufficient evidence, not a gap in availability that can simply be worked around.

What this means in practice if you are exploring your options

For most people reading this page, the practical question is whether tirzepatide alone is suitable for them, and that is a question with a clear, licensed answer. Adults with a BMI of 30 or above, or 27 or above alongside a weight-related condition such as high blood pressure, high cholesterol, obstructive sleep apnoea or type 2 diabetes, may be eligible for tirzepatide through a private prescription following clinical assessment. Lower BMI thresholds can apply for some ethnic backgrounds under UK guidance. The prescriber assesses the full picture, not BMI in isolation.

On the cost side, it is worth knowing that Eli Lilly's UK list price for Mounjaro rose significantly from September 2025, context that is relevant if you are weighing up routes to treatment. Our overview of the Mounjaro price increase covers what that means for private patients. Anyone exploring weight-loss treatment more broadly will find licensed options (and honest information about what each involves) without having to wade through the noise of unlicensed combinations.

If and when a cagrilintide-tirzepatide combination reaches regulatory approval (in the UK or elsewhere) that will be a significant clinical development and we will cover it. Until then, the evidence base simply does not support its use outside a clinical trial. A prescriber at our GPhC-registered pharmacy can discuss what is currently licensed and appropriate for you. Start your free consultation if you'd like that conversation.